ParkinsonCanadaV1, PubMed, Corpus, bibRecord, 000812

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Identifieur interne : 000812 ( PubMed/Corpus ); précédent : 000811; suivant : 000813

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Auteurs : Jamie Eberling ; Lona Vincent ; Jennifer G. Goldman ; Daniel Weintraub ; Jaime Kulisevsky ; Connie Marras ; Glenn Stebbins ; Karl Kieburtz

Source :

Journal of Parkinson's disease [ 1877-718X ] ; 2014.

RBID : pubmed:24989876

English descriptors

KwdEn :
- Clinical Trials as Topic, Cognition Disorders (diagnosis), Cognition Disorders (etiology), Cognition Disorders (therapy), Disease Progression, Humans, Neuropsychological Tests, Parkinson Disease (complications), Parkinson Disease (psychology), Quality of Life.
MESH :
- complications : Parkinson Disease.
- diagnosis : Cognition Disorders.
- etiology : Cognition Disorders.
- psychology : Parkinson Disease.
- therapy : Cognition Disorders.
- Clinical Trials as Topic, Disease Progression, Humans, Neuropsychological Tests, Quality of Life.

Abstract

Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to define the path for therapeutic development in this area. In the absence of a well-defined path for the approval of therapies that target PD-MCI, pharmaceutical companies are unlikely to pursue this indication. In order to move forward and improve the quality of life for PD patients, it is imperative for the field to have consensus on the definition of PD-MCI, the best instruments to measure cognitive decline, and a strategy for future clinical trials.

DOI: 10.3233/JPD-140385
PubMed: 24989876

Links to Exploration step

pubmed:24989876

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.</title>
<author><name sortKey="Eberling, Jamie" sort="Eberling, Jamie" uniqKey="Eberling J" first="Jamie" last="Eberling">Jamie Eberling</name>
<affiliation><nlm:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vincent, Lona" sort="Vincent, Lona" uniqKey="Vincent L" first="Lona" last="Vincent">Lona Vincent</name>
<affiliation><nlm:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G" last="Goldman">Jennifer G. Goldman</name>
<affiliation><nlm:affiliation>Rush University Medical Center, Chicago, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><nlm:affiliation>University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation><nlm:affiliation>Sant Pau Hospital, Barcelona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation><nlm:affiliation>University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation><nlm:affiliation>Rush University Medical Center, Chicago, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><nlm:affiliation>University of Rochester, Rochester, NY, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24989876</idno>
<idno type="pmid">24989876</idno>
<idno type="doi">10.3233/JPD-140385</idno>
<idno type="wicri:Area/PubMed/Corpus">000812</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000812</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.</title>
<author><name sortKey="Eberling, Jamie" sort="Eberling, Jamie" uniqKey="Eberling J" first="Jamie" last="Eberling">Jamie Eberling</name>
<affiliation><nlm:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vincent, Lona" sort="Vincent, Lona" uniqKey="Vincent L" first="Lona" last="Vincent">Lona Vincent</name>
<affiliation><nlm:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Goldman, Jennifer G" sort="Goldman, Jennifer G" uniqKey="Goldman J" first="Jennifer G" last="Goldman">Jennifer G. Goldman</name>
<affiliation><nlm:affiliation>Rush University Medical Center, Chicago, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation><nlm:affiliation>University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation><nlm:affiliation>Sant Pau Hospital, Barcelona, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation><nlm:affiliation>University of Toronto, Toronto, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn" sort="Stebbins, Glenn" uniqKey="Stebbins G" first="Glenn" last="Stebbins">Glenn Stebbins</name>
<affiliation><nlm:affiliation>Rush University Medical Center, Chicago, IL, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><nlm:affiliation>University of Rochester, Rochester, NY, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Parkinson's disease</title>
<idno type="eISSN">1877-718X</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Cognition Disorders (diagnosis)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cognition Disorders (therapy)</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (psychology)</term>
<term>Quality of Life</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Neuropsychological Tests</term>
<term>Quality of Life</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to define the path for therapeutic development in this area. In the absence of a well-defined path for the approval of therapies that target PD-MCI, pharmaceutical companies are unlikely to pursue this indication. In order to move forward and improve the quality of life for PD patients, it is imperative for the field to have consensus on the definition of PD-MCI, the best instruments to measure cognitive decline, and a strategy for future clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24989876</PMID>
<DateCreated><Year>2014</Year>
<Month>12</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>08</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1877-718X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>4</Volume>
<Issue>4</Issue>
<PubDate><Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Journal of Parkinson's disease</Title>
<ISOAbbreviation>J Parkinsons Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.</ArticleTitle>
<Pagination><MedlinePgn>585-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3233/JPD-140385</ELocationID>
<Abstract><AbstractText>Cognitive impairment is a common occurrence in Parkinson's disease (PD), although the severity and specific presentation varies across patients. Initial deficits, including mild cognitive impairment (PD-MCI), may remain stable or in many cases, may progress over variable lengths of time to Parkinson's disease dementia (PDD). As there are currently no marketed treatments for milder forms of cognitive impairment, an opportunity exists to define the path for therapeutic development in this area. In the absence of a well-defined path for the approval of therapies that target PD-MCI, pharmaceutical companies are unlikely to pursue this indication. In order to move forward and improve the quality of life for PD patients, it is imperative for the field to have consensus on the definition of PD-MCI, the best instruments to measure cognitive decline, and a strategy for future clinical trials.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eberling</LastName>
<ForeName>Jamie</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vincent</LastName>
<ForeName>Lona</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goldman</LastName>
<ForeName>Jennifer G</ForeName>
<Initials>JG</Initials>
<AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Weintraub</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kulisevsky</LastName>
<ForeName>Jaime</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Sant Pau Hospital, Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marras</LastName>
<ForeName>Connie</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>University of Toronto, Toronto, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stebbins</LastName>
<ForeName>Glenn</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kieburtz</LastName>
<ForeName>Karl</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>University of Rochester, Rochester, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P50 NS053488</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>J Parkinsons Dis</MedlineTA>
<NlmUniqueID>101567362</NlmUniqueID>
<ISSNLinking>1877-7171</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837</RefSource>
<PMID Version="1">17542011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2014 Apr 15;29(5):622-33</RefSource>
<PMID Version="1">24757111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 May 15;23(7):998-1005</RefSource>
<PMID Version="1">18381647</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Sep 24;361(13):1268-78</RefSource>
<PMID Version="1">19776408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1999 Mar;56(3):303-8</RefSource>
<PMID Version="1">10190820</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Psychiatry. 1984 Nov;141(11):1356-64</RefSource>
<PMID Version="1">6496779</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Psychiatr Res. 1975 Nov;12(3):189-98</RefSource>
<PMID Version="1">1202204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Gerontol Geriatr Suppl. 2004;(9):387-91</RefSource>
<PMID Version="1">15207437</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2003 Nov 11;61(9):1222-8</RefSource>
<PMID Version="1">14610124</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Alzheimer Dis Assoc Disord. 2001 Apr-Jun;15(2):89-95</RefSource>
<PMID Version="1">11391090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 Nov;132(Pt 11):2958-69</RefSource>
<PMID Version="1">19812213</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2009 Nov 24;73(21):1738-45</RefSource>
<PMID Version="1">19933974</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 Jan;67(1):64-70</RefSource>
<PMID Version="1">20065131</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Jul 15;25(9):1170-6</RefSource>
<PMID Version="1">20310053</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Nov 9;75(19):1717-25</RefSource>
<PMID Version="1">21060094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Mar;27(3):349-56</RefSource>
<PMID Version="1">22275317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Geriatr Psychiatry Neurol. 2012 Jun;25(2):100-6</RefSource>
<PMID Version="1">22689702</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA Neurol. 2013 May;70(5):580-6</RefSource>
<PMID Version="1">23529397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Jul 23;81(4):346-52</RefSource>
<PMID Version="1">23794682</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Sep;19(9):812-7</RefSource>
<PMID Version="1">23773412</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jul;28(8):1034-49</RefSource>
<PMID Version="1">23426759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jul;28(8):1097-103</RefSource>
<PMID Version="1">23630134</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64</RefSource>
<PMID Version="1">23781007</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2014 Apr 15;29(5):584-96</RefSource>
<PMID Version="1">24757108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2014 Apr 15;29(5):608-21</RefSource>
<PMID Version="1">24757110</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2008;14(2):93-101</RefSource>
<PMID Version="1">17707678</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS671149</OtherID>
<OtherID Source="NLM">PMC4371591</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FDA</Keyword>
<Keyword MajorTopicYN="N">Parkinson's</Keyword>
<Keyword MajorTopicYN="N">clinical trial</Keyword>
<Keyword MajorTopicYN="N">cognition</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>7</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>8</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24989876</ArticleId>
<ArticleId IdType="pii">UNQ76R7877966374</ArticleId>
<ArticleId IdType="doi">10.3233/JPD-140385</ArticleId>
<ArticleId IdType="pmc">PMC4371591</ArticleId>
<ArticleId IdType="mid">NIHMS671149</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000812 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000812 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24989876
   |texte=   Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24989876" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki